Phase 1 Lupus Trial, Recruiting (NCT06975787)

Phase 1 Lupus Trial, Recruiting NCT06975787 Sponsor: Regeneron Pharmaceuticals Condition: Lupus

Printed from Voxsanity (voxsanity.com.au) — NCT06975787 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lupus

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with Systemic Lupus Erythematosus (SLE) — an autoimmune disease — along with a related kidney condition called Lupus Nephritis (LN)
Your disease has either not responded to previous treatments or has come back after treatment (confirm with trial site for full details)

Who may not be able to join:

You have a history of, or currently have, serious or unstable lupus-related brain or mental health problems that may need urgent medical care or a hospital stay
You have had, or currently have, an overlapping condition called mixed connective tissue disease or systemic sclerosis within the past 12 months
You have experienced a severe or life-threatening blood clotting disorder related to antiphospholipid syndrome within the past 12 months

Important: There are additional eligibility requirements not listed here, so always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals

Phone: 844-734-6643

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06975787

Sponsor: Regeneron Pharmaceuticals

Phase: Phase 1

Status: Recruiting

Condition: Lupus

Trial contact: 844-734-6643

More information: https://clinicaltrials.gov/study/NCT06975787

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with Systemic Lupus Erythematosus (SLE) — an autoimmune disease — along with a related kidney condition called Lupus Nephritis (LN)
Your disease has either not responded to previous treatments or has come back after treatment (confirm with trial site for full details)

Who may not be able to join:

You have a history of, or currently have, serious or unstable lupus-related brain or mental health problems that may need urgent medical care or a hospital stay
You have had, or currently have, an overlapping condition called mixed connective tissue disease or systemic sclerosis within the past 12 months
You have experienced a severe or life-threatening blood clotting disorder related to antiphospholipid syndrome within the past 12 months

Important: There are additional eligibility requirements not listed here, so always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Regeneron Pharmaceuticals

Registry

ClinicalTrials.gov

Start date

22 December 2025

Est. completion

9 September 2029

Where this trial is recruiting

🇫🇷 France 🇩🇪 Germany 🇰🇷 South Korea 🇪🇸 Spain 🇹🇼 Taiwan 🇺🇸 United States

Primary endpoints

Occurrence of Dose Limiting Toxicities (DLT); Occurrence of Treatment Emergent Adverse Events (TEAEs); Severity of TEAEs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov